- Home
- VIAV vs KNSA Comparison
VIAV vs KNSA Comparison
Compare VIAV & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIAV
- KNSA
- Stock Information
- Founded
- VIAV 1923
- KNSA 2015
- Country
- VIAV United States
- KNSA United Kingdom
- Employees
- VIAV N/A
- KNSA N/A
- Industry
- VIAV Semiconductors
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- VIAV Technology
- KNSA Health Care
- Exchange
- VIAV Nasdaq
- KNSA Nasdaq
- Market Cap
- VIAV 2.1B
- KNSA 2.1B
- IPO Year
- VIAV 1993
- KNSA 2018
- Fundamental
- Price
- VIAV $9.99
- KNSA $27.13
- Analyst Decision
- VIAV Buy
- KNSA Strong Buy
- Analyst Count
- VIAV 8
- KNSA 5
- Target Price
- VIAV $12.69
- KNSA $38.80
- AVG Volume (30 Days)
- VIAV 2.3M
- KNSA 1.1M
- Earning Date
- VIAV 08-07-2025
- KNSA 07-22-2025
- Dividend Yield
- VIAV N/A
- KNSA N/A
- EPS Growth
- VIAV N/A
- KNSA N/A
- EPS
- VIAV 0.02
- KNSA N/A
- Revenue
- VIAV $1,045,800,000.00
- KNSA $481,166,000.00
- Revenue This Year
- VIAV $10.06
- KNSA $37.21
- Revenue Next Year
- VIAV $7.08
- KNSA $5.32
- P/E Ratio
- VIAV $481.15
- KNSA N/A
- Revenue Growth
- VIAV 3.34
- KNSA 59.45
- 52 Week Low
- VIAV $6.75
- KNSA $17.38
- 52 Week High
- VIAV $12.91
- KNSA $30.69
- Technical
- Relative Strength Index (RSI)
- VIAV 62.49
- KNSA 44.42
- Support Level
- VIAV $9.96
- KNSA $27.08
- Resistance Level
- VIAV $10.30
- KNSA $28.86
- Average True Range (ATR)
- VIAV 0.23
- KNSA 1.04
- MACD
- VIAV 0.08
- KNSA -0.32
- Stochastic Oscillator
- VIAV 74.59
- KNSA 16.05
About VIAV Viavi Solutions Inc.
Viavi Solutions Inc. is an international provider of network test, monitoring, and assurance solutions to communications service providers, enterprises, network equipment manufacturers, civil government, military and avionics customers. The company also offers high-performance thin-film optical coatings, providing light management solutions to anti-counterfeiting, 3D sensing, electronics, automotive, defense, and instrumentation markets. Its operating segments include Network Enablement, Service Enablement, and Optical Security and Performance Products. Geographically, it derives a majority of its revenue from the United States. Additionally, it manufactures and sells optical filters for 3D sensing products that allow facial recognition security authentication for mobile devices.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.